Tevogen (TVGN) provided stockholders a detailed overview of its artificial intelligence initiative, Tevogen.AI, aimed at integrating advanced machine learning into its ExacTcell technology to enhance target identification and preclinical processes. Tevogen.AI currently has two proprietary technologies, PredicTcell and AdapTcell, both with patents pending. The company also highlighted strategic partnerships with Microsoft (MSFT), providing AI expertise and cloud computing infrastructure, and Databricks, supplying data engineering and analytics capabilities. Tevogen plans to expand its headquarters for the Tevogen.AI team.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVGN:
- Tevogen announces planned expansion of TVGN 489’s target population
- Tevogen CEO says business model addresses biopharma industry challenges
- Biotech Alert: Searches spiking for these stocks today
- Tevogen CEO to join dialogue on Paths to Liquidity
- Tevogen sees launch year oncology business revenue $1B